Format

Send to

Choose Destination
Mult Scler Relat Disord. 2019 Nov 6;38:101503. doi: 10.1016/j.msard.2019.101503. [Epub ahead of print]

Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis.

Author information

1
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address: alexlau@cuhk.edu.hk.
2
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong SAR, China.
3
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
4
Department of Neurology, Center of Clinical Neuroscience, Carl Gustav Carus University Clinic, University Hospital of Dresden, Dresden, Germany.

Abstract

Pneumocystis jirovecii pneumonia (PJP) is a known risk in patients with chronic lymphocytic leukemia treated with alemtuzumab (Campath®). However, no recommendation for PJP prophylaxis for alemtuzumab use in multiple sclerosis (Lemtrada®) and no known associated PJP has been reported to date. We report a patient who developed PJP two months after receiving the first course of Lemtrada, and fully recovered after receiving cotrimoxazole treatment. We should remain vigilant of opportunistic infections in patients who develop pneumonitis and evaluate the need for PJP prophylaxis during Lemtrada treatment.

KEYWORDS:

Alemtuzumab; Multiple sclerosis; Pneumocystis jirovecii; Pneumocystis pneumonia; Prophylaxis

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center